SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-045717
Filing Date
2024-04-19
Accepted
2024-04-19 07:36:28
Documents
21
Period of Report
2024-05-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A kpti-20240417.htm   iXBRL DEF 14A 2347815
2 GRAPHIC img95390205_0.jpg GRAPHIC 33329
3 GRAPHIC img95390205_1.jpg GRAPHIC 8774
4 GRAPHIC img95390205_2.jpg GRAPHIC 33329
5 GRAPHIC img95390205_3.jpg GRAPHIC 114247
6 GRAPHIC img95390205_4.jpg GRAPHIC 247114
7 GRAPHIC img95390205_5.jpg GRAPHIC 217260
8 GRAPHIC img95390205_6.jpg GRAPHIC 232988
9 GRAPHIC img95390205_7.jpg GRAPHIC 411920
10 GRAPHIC img95390205_8.jpg GRAPHIC 373461
  Complete submission text file 0000950170-24-045717.txt   7283256

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20240417.xsd EX-101.SCH 29773
24 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20240417_htm.xml XML 165375
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36167 | Film No.: 24855627
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)